Literature DB >> 33547578

Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD.

Michele Staton1,2, Hannah K Knudsen3,4, Sharon L Walsh3,4, Carrie Oser4,5, Erika Pike4, Michelle Lofwall3,4.   

Abstract

BACKGROUND: Despite a growing body of empirical support for the effectiveness of extended-release naltrexone (XR-NTX) to reduce opioid relapse among people with opioid use disorder (OUD) transitioning from a correctional facility to the community, continuity of care following release remains challenging. This paper describes a research-based adaptation of a state's standard of care XR-NTX protocol using the ADAPT-ITT framework for delivery in a non-traditional, non-treatment, community criminal justice setting (P&P office), as well as the expansion of services by a local Federally Qualified Health Center (FQHC) provider who would, for the first time, be going to the jail and P&P office to provide XR-NTX and related treatment.
METHOD: The present study focuses on the first seven phases (Assessment through Training) of the ADAPT-ITT framework in the adaptation of the Department of Corrections (DOC) protocol in preparation for a pilot trial for induction in a rural jail and during the transition to a rural community. Expert clinical review and focus groups with key stakeholders in criminal justice supervision and the local providers in the FQHC informed the needed adaptations to the existing XR-NTX protocol for initiation at the jail and ongoing administrations in the community.
RESULTS: Findings from stakeholder focus groups, study team review, topical expert review, and a theater test suggested that there were critical adaptations needed in both content and context at the patient and clinic level.
CONCLUSION: Health and justice officials should consider the need to tailor and adapt evidence-based approaches for real-world locations that high-risk, justice-involved individuals visit in order to reduce barriers and increase access to critically needed treatment for OUD.

Entities:  

Keywords:  Community supervision; OUD; Rural offenders; XR-NTX

Year:  2021        PMID: 33547578      PMCID: PMC7864137          DOI: 10.1186/s40352-021-00130-0

Source DB:  PubMed          Journal:  Health Justice        ISSN: 2194-7899


  32 in total

1.  Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013.

Authors:  Brendan Saloner; Shankar Karthikeyan
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

2.  Extended-release naltrexone for opioid use disorder started during or following incarceration.

Authors:  Thomas Lincoln; Benjamin D Johnson; Patrick McCarthy; Ellen Alexander
Journal:  J Subst Abuse Treat       Date:  2017-04-06

3.  Opioid analgesics and heroin: Examining drug misuse trends among a sample of drug treatment clients in Kentucky.

Authors:  Grant A Victor; Robert Walker; Jennifer Cole; T K Logan
Journal:  Int J Drug Policy       Date:  2017-05-13

Review 4.  Pharmacological interventions for drug-using offenders.

Authors:  Amanda E Perry; Matthew Neilson; Marrissa Martyn-St James; Julie M Glanville; Rachael McCool; Steven Duffy; Christine Godfrey; Catherine Hewitt
Journal:  Cochrane Database Syst Rev       Date:  2013-12-19

5.  Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.

Authors:  Peter D Friedmann; Donna Wilson; Randall Hoskinson; Michael Poshkus; Jennifer G Clarke
Journal:  J Subst Abuse Treat       Date:  2017-04-19

6.  A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kevin E O'Grady; Terrence T Fitzgerald; Frank J Vocci
Journal:  Drug Alcohol Depend       Date:  2017-01-11       Impact factor: 4.492

7.  Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

Authors:  Joshua D Lee; Peter D Friedmann; Timothy W Kinlock; Edward V Nunes; Tamara Y Boney; Randall A Hoskinson; Donna Wilson; Ryan McDonald; John Rotrosen; Marc N Gourevitch; Michael Gordon; Marc Fishman; Donna T Chen; Richard J Bonnie; James W Cornish; Sean M Murphy; Charles P O'Brien
Journal:  N Engl J Med       Date:  2016-03-31       Impact factor: 91.245

8.  A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.

Authors:  David Farabee; Timothy Condon; Kevin A Hallgren; Barbara McCrady
Journal:  J Subst Abuse Treat       Date:  2020-07-06

9.  American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

Authors:  Kyle Kampman; Margaret Jarvis
Journal:  J Addict Med       Date:  2015 Sep-Oct       Impact factor: 3.702

10.  Adaptation of the African couples HIV testing and counseling model for men who have sex with men in the United States: an application of the ADAPT-ITT framework.

Authors:  Patrick S Sullivan; Rob Stephenson; Beau Grazter; Gina Wingood; Ralph Diclemente; Susan Allen; Colleen Hoff; Laura Salazar; Lamont Scales; Jeanne Montgomery; Ann Schwartz; Jasper Barnes; Kristina Grabbe
Journal:  Springerplus       Date:  2014-05-16
View more
  1 in total

1.  "There's No Heroin Around Anymore. It's All Fentanyl." Adaptation of an Opioid Overdose Prevention Counseling Approach to Address Fentanyl Overdose: Formative Study.

Authors:  Vanessa M McMahan; Justine Arenander; Tim Matheson; Audrey M Lambert; Sarah Brennan; Traci C Green; Alexander Y Walley; Phillip O Coffin
Journal:  JMIR Form Res       Date:  2022-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.